SPRY4 (Sprouty RTK Signaling Antagonist 4) is a protein-coding gene located on chromosome 5q31.3 in humans, encoding a 322-amino acid intracellular protein with a molecular weight of approximately 32.5 kDa . It belongs to the Sprouty family of proteins, which are cysteine- and proline-rich negative regulators of receptor tyrosine kinase (RTK) signaling pathways, particularly the mitogen-activated protein kinase (MAPK) pathway . SPRY4 functions as a feedback inhibitor of growth factor signaling, modulating cellular processes such as proliferation, migration, apoptosis, and oxidative stress .
SPRY4 contains conserved structural domains critical for its regulatory functions:
The PEST sequence accelerates SPRY4 degradation, while its CR domain binds phosphatidylinositol bisphosphate (PIP2), blocking PLCγ hydrolysis and downstream PKC/Ca²⁺ signaling .
SPRY4 modulates multiple signaling cascades:
SPRY4 binds free SOS1 or the Grb2-SOS1 complex, preventing Ras activation and suppressing ERK phosphorylation . This inhibition is context-dependent:
FGF Signaling: Disrupts FGF-induced ERK activation via SOS1 sequestration .
Vascular Endothelial Growth Factor (VEGF): Binds Raf1 to inhibit VEGF-A-induced ERK signaling .
Sphingosine-1-Phosphate (S1P): Suppresses S1P/PLCγ/PKC and AKT pathways .
SPRY4 exhibits dual roles as a tumor suppressor or oncogene, depending on context:
SPRY4 expression is higher in healthy cartilage and decreased in OA, correlating with disease severity . Knockdown in healthy chondrocytes induces hypertrophy, senescence, and ECM degradation, while overexpression in degenerated chondrocytes restores glycosaminoglycan (GAG) content and reduces ECM proteases (e.g., MMP13, ADAMTS5) .
SPRY4 is widely expressed in human tissues, with high RNA/protein levels observed in:
SPRY4 belongs to the Spry family of proteins that are rich in cysteine and proline. It functions primarily as an inhibitor of the mitogen-activated protein kinase (MAPK) signaling pathway . As an intracellular protein, SPRY4 translocates to the plasma membrane upon activation, with its structural domain located in the cytoplasmic membrane . With a molecular weight of approximately 32.541 KDa, SPRY4 is involved in various cellular biological functions including embryonic development, organogenesis, cell apoptosis and proliferation, oxidative stress, inflammatory response, and ischemic injury under both physiological and pathological conditions .
SPRY4 is characterized by several key structural features:
| Feature | Details |
|---|---|
| Gene Symbol | hSPRY4 (human), mSPRY4 (mouse) |
| Chromosome Location | 5q31.3 (human), 18 B3 (mouse) |
| Molecular Weight | 32.6 kDa |
| Protein Isoelectric Point | 8.25 |
The protein contains a shared C-terminal cysteine-rich domain that is characteristic of the SPRY family . Mammalian SPRY proteins can form cooperative homo- and hetero-oligomers, which contribute to their regulatory functions . The protein structure is particularly rich in cysteine and proline residues, which are important for its functional properties .
SPRY4 suppresses ERK MAPK activity induced by multiple growth factors, including FGF, vascular endothelial cell growth factor, and nerve growth factor in various cell types . Its point of action within the signaling cascade can be cell type-specific and growth factor-specific, but it primarily acts at the level of RAS and/or RAF1 .
Experimental evidence demonstrates that induction of SPRY4 by FGF2 or GDNF can be completely abrogated by chemical inhibitors of MEK1/2 but not by inhibitors of other canonical pathways (PI3K, PKC, p38 MAPK, or JNK MAPK), indicating relative specificity for the ERK MAPK pathway . When SPRY4 is disrupted via CRISPR/Cas9 gene editing, cells exhibit increased ERK activity within minutes of exposure to FGF2, suggesting that even low basal levels of SPRY4 are sufficient to regulate ERK MAPK signaling .
Several complementary methodologies are employed to study SPRY4 expression:
RNA expression profile analysis through databases like the Genotype-Tissue Expression Project
Immunohistochemical staining of tissue sections to detect protein localization
Reporter systems such as the H2B-Venus fluorophore to visualize SPRY4-expressing cells in situ
Quantitative single-cell analysis using specialized reporter systems like ERK-KTR
Co-immunostaining with relevant markers (e.g., GFRA1, MCAM) to identify specific SPRY4-expressing cell populations
Analysis of RNA expression profiles shows that SPRY4 is widely expressed across human tissues . The regulation of SPRY4 appears to be tissue-specific and context-dependent. At the transcriptional level, growth factors like FGF2 or GDNF can induce SPRY4 expression through the ERK MAPK pathway, as demonstrated by the complete abrogation of this induction by MEK1/2 inhibitors .
In the context of spermatogonial stem cells, SPRY4 expression decreases during differentiation, suggesting a developmental regulation of its expression . The use of a nuclear-localized SPRY4 reporter (H2B-Venus) has revealed that SPRY4 is expressed not only in certain germ cells but also in various somatic cell types, including peritubular, Leydig, endothelial, and Sertoli cells, though with varying intensity .
Research demonstrates that growth factor signaling through the ERK MAPK pathway in spermatogonial stem cells is tightly regulated within a narrow range through distinct intracellular negative feedback regulators, including SPRY4 . Undifferentiated spermatogonia in vivo exhibit high levels of SPRY4 mRNA . When SPRY4 is ablated, disruption of ERK MAPK signaling downstream of RAS occurs, leading to a shift in cell fate toward early differentiation with concomitant loss of stem cell activity .
Using a mouse SPRY4 reporter line, researchers have shown that the adult spermatogonial stem cell population in vivo is demarcated by strong SPRY4 promoter activity . Specifically, SPRY4 is expressed in A single, A pair, and A aligned undifferentiated spermatogonia, with A single spermatogonia considered to be the primary SSC-containing population .
Single-cell RNA sequencing (scRNA-seq) provides powerful insights into SPRY4's role in cellular differentiation through several analytical steps:
Data processing and quality control:
Normalization and dimension reduction:
Cell-type identification:
Trajectory analysis:
Construction of developmental trajectories using algorithms like Monocle3
Application of reversed graph embedding to learn gene expression sequence changes
Construction of "branched" trajectories corresponding to cellular "decisions"
Selection of appropriate nearest neighbor graphs for Leiden community detection
This methodological approach has successfully identified distinct spermatogonial cell populations with varying SPRY4 expression levels, revealing its role in maintaining stem cell identity versus promoting differentiation .
A heterozygous variant in the SPRY4 gene has been identified in infertile patients and is associated with early embryonic arrest in humans . Researchers have conducted both in vitro and in vivo studies to investigate the effects of this pathogenic variant .
The study identified a pathogenic SPRY4 variant as a genetic factor contributing to early embryonic arrest in infertile patients . This finding suggests that proper SPRY4 function is essential for early embryonic development, and disruption through genetic variants can lead to developmental arrest and subsequent infertility .
The precise mechanisms likely involve dysregulation of the MAPK signaling pathway, which is normally inhibited by SPRY4. Since SPRY4 plays important roles in embryonic development and organogenesis , alterations in its function could disrupt critical developmental processes necessary for successful embryo formation.
To investigate SPRY4's interaction with RAS/RAF in the ERK MAPK pathway, several methodological approaches have proven effective:
Genetic manipulation:
Signaling dynamics analysis:
Pathway specificity determination:
Molecular localization:
Examination of SPRY4 translocation to the plasma membrane upon activation
Co-localization studies with RAS/RAF components using immunofluorescence or advanced microscopy techniques
These approaches collectively provide a comprehensive understanding of how SPRY4 regulates the ERK MAPK pathway at the level of RAS/RAF, with implications for growth factor-dependent cellular processes .
Based on the research methodologies described in the search results, several experimental approaches have proven effective for studying SPRY4's developmental roles:
Reporter systems:
Immunostaining techniques:
Genetic manipulation:
Quantitative analysis:
Single-cell transcriptomics:
These approaches have successfully revealed SPRY4's importance in maintaining stem cell populations and regulating differentiation during development, particularly in the context of the mammalian germline .
SPRY4 functions as an inhibitor of the receptor-transduced mitogen-activated protein kinase (MAPK) signaling pathway . It is positioned upstream of RAS activation and impairs the formation of active GTP-RAS . By doing so, SPRY4 suppresses the epidermal growth factor receptor (EGFR)-transduced MAPK signaling pathway . This inhibition is crucial for regulating cellular responses to growth signals and maintaining cellular homeostasis.
The MAPK/ERK signaling pathway, regulated by SPRY4, is one of the most widespread regulatory mechanisms in eukaryotic cell biology . Dysregulation of this pathway can lead to various diseases, including cancer. Therefore, SPRY4’s role as a negative regulator is vital for preventing uncontrolled cell proliferation and tumorigenesis.
Human recombinant SPRY4 is used in research to study its inhibitory effects on MAPK signaling and its potential therapeutic applications. Understanding SPRY4’s function and regulation can provide insights into developing targeted therapies for diseases associated with aberrant RTK signaling.